Abbisko's Lavengratinib Shows Early Growth Benefit In Children With Achondroplasia

(RTTNews) - Abbisko Therapeutics Co., Ltd. (02256.HK) announced positive preliminary Phase II results for avengratinib (...

By Dhallo News · September 21, 2026 at 9:17 AM IST

(RTTNews) - Abbisko Therapeutics Co., Ltd. (02256.HK) announced positive preliminary Phase II results for avengratinib (ABSK061), used for the treatment for achondroplasia, a genetic condition that affects bone growth and is the most common form of dwarfism. The early data showed

SOURCE: Nasdaq

ORIGINAL REPORT: Click here

DHALLO EDITORIAL STATUS: Aggregated & reviewed

Have feedback on this article?Report error or suggestion

Abbisko's Lavengratinib Shows Early Growth Benefit In Children With Achondroplasia

Read More from Markets

Tata Capital, Tata Power, and more: Tata stocks fall as Tata Trusts-Tata Sons battle intensifies - Check the latest

Kuehne+Nagel Signs Long-term Strategic Collaboration With Amazon

Beyond modern masters: Indian art is being reshaped by confident domestic buyers as auction market triples

5 minutes. The news that matters.